

Attorney Docket No.  
02973.00031

Serial No.  
TBA

INFORMATION DISCLOSURE CITATION  
Sheet 1 of 2

Applicant(s): Thanos HALAZONETIS et al.

Filing Date: Herewith

Group:

U.S. PATENT DOCUMENTS


Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
SSM	94/08241	4/1994	WO				
SSM	95/17213	6/1995	WO				
SSM	0 518 650	12/1992	EP				
SSM	94/12202	1994	WO				
SSM	94/10306	5/1994	WO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

SSM	Coller et al., "Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M-induced Cleavage and Inactivation," <i>J. Biol. Chem.</i> , 268(28):20741-20743 (1993)
SSM	Couder et al., "Synthesis and Biological Activities of $\psi(\text{CH}_2\text{NH})$ Pseudopeptide Analogues of the C-terminal Hexapeptide of Neurotensin," <i>Internat. J. Peptide &amp; Protein Res.</i> , 41(2):181-184 (1993)
SSM	DalPozzo et al., "H-Gly-His $\psi$ (NHCO)Lys-OH, Partially Modified <i>Retro-Inverso</i> Analogue of the Growth Factor Glycyl-L-histidyl-L-lysine with Enhanced enzymatic Stability," <i>Int. J. Peptide Protein Res.</i> , 41:561-566 (1993)
SSM	Hupp et al., "Regulation of the Cryptic Sequence-Specific DNA-Binding Function of p53 by Protein Kinases," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LIX, pp. 195-205 (1994)
SSM	Hupp et al., "Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53," <i>Cell</i> , 83:237-245 (1995)
SSM	Shaw et al., "Regulation of Specific DNA Binding by p53: Evidence for a Role of o-Glycosylation and Charged Residues at the Carboxy-terminus," <i>Oncogene</i> , 12:921-930 (1996)
SSM	Takenaka et al., "Regulation of the Sequence-Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases," <i>J. Biol. Chem.</i> , 270(10):5405-5411 (1995)
SSM	Tanigaki et al., "The Peptide Binding Specificity of HLA-B27 Subtypes," <i>Immunogenetics</i> , 40:192-198 (1994)
SSM	Powell et al., "Peptide Stability in Drug Development. II. Effect of Single Amino acid Substitution and Glycosylation on Peptide Reactivity in Human Serum," <i>Pharmaceutical Research</i> , 10(9):1268-1273 (1993)
SSM	Brady et al., "Reflections on a Peptide," <i>Nature</i> , 368:692-693 (1994)
SSM	Hupp et al., Allosteric Activation of Latent p53 Tetramers," <i>Current Biology</i> , 4(10):865-875 (1994)
SSM	Wade-Evans et al., "Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53," <i>EMBO J.</i> , 4:699-706 (1985)
SSM	Finlay et al., "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093 (1989)
SSM	Soussi et al., "Structural Aspects of the p53 Protein in Relation to Gene Evolution," <i>Oncogene</i> , 5:945-952 (1990)
SSM	Hupp et al., "Regulation of the Specific DNA Binding Function of p53," <i>Cell</i> , 71:857-886 (1992)
SSM	Hruby, "Conformational and Topographical Consideration in the Design of Biologically Active Peptides," <i>Biopolymers</i> , 33:1073-1082 (1993)



Attorney Docket No.  
02973.00031

Serial No.  
TBA

INFORMATION DISCLOSURE CITATION

Sheet 1 of 2

Applicant(s): Thanos HALAZONETIS et al.

Filing Date: Herewith

Group:

1040 U.S. PTO  
09/829922

04/11/01

SSH	Hupp et al., "Activation of the Cryptic DNA Binding Function of Mutant Forms of p53," <i>Nucleic Acids Res.</i> , 21:3167-3174 (1993)
SSH	Fujiwara et al., "A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis," <i>Cancer Res.</i> , 53:4129-4133 (1993)
SSH	Halazonetis et al., "Wild-Type p53 Adopts a 'Mutant'-like Conformation when Bound to DNA," <i>EMBO J.</i> , 12:1021-1028 (1993)
SSH	Halazonetis et al., "Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Binding Domain and Restore DNA Binding to Select p53 Mutants," <i>EMBO J.</i> , 12:5057-5064 (1993)
SSH	Bugg et al., "Drugs by Design," <i>Sci. Am.</i> , 269:92-98 (1993)
SSH	Friend, "p53: A Glimpse at the Puppet Behind the Shadow Play," <i>Science</i> , 265:334-335 (1994)
SSH	Cho et al., "Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations," <i>Science</i> , 265:346-355 (1994)
SSH	Clore et al., "High Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR," <i>Science</i> , 265:386-391 (1994)
SSH	Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis," <i>Science</i> , 265:391-394 (1994)
SSH	Cox et al., " <i>Xenopus</i> p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced upon DNA Damage in Somatic Cells," <i>Oncogene</i> , 9:2951-2959 (1994)
SSH	Jameson et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis," <i>Nature</i> , 368:744-746 (1994)
SSH	Moore, "Designing Peptide Mimetics," <i>Trends Pharmacol. Sci.</i> , 15:124-129 (1994)
SSH	Dean, "Recent Advances in Drug Design Methods" Where Will They Lead?" <i>BioEssays</i> , 16:683-687 (1994)
SSH	Naoko Arai et al., "Immunologically Distinct p53 Molecules Generated by Alternative Splicing," <i>Molecular and Cellular Biology</i> , Vol 6, No. 9, September 1986, p. 3232-3239
SSH	Stryer. <i>Biochemistry</i> Second Edition, p. 13-17

EXAMINER

*[Signature]*

DATE CONSIDERED

6/3/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*\*Copies of references not provided at the time of this submission.